LTGO Latigo Biotherapeutics, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $5.04M and sold $0 on the open market.
LTGO revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$25.8M, EPS -27.59
- Quarter ended Mar 31, 2026: revenue n/a, net income −$23.0M
- Quarter ended Jun 30, 2025: revenue n/a, net income −$25.8M, EPS -36.52
- Quarter ended Mar 31, 2025: revenue n/a, net income −$21.0M
Recent LTGO insider trades
- Aug 10, 2026: Tananbaum James B. bought 140,000 shares ($2.52M)
- Aug 10, 2026: Foresite Capital Fund V, L.P. bought 140,000 shares ($2.52M)
5%+ owners
- James B. Tananbaum: 14.5% (Schedule 13D, filed Aug 17, 2026)
- RA Capital Management, L.P.: 8.4% (Schedule 13G, filed Aug 17, 2026)
- Deep Track Capital, LP: 7.0% (Schedule 13G, filed Aug 13, 2026)
- AI Biotechnology LLC: 5.0% (Schedule 13G, filed Aug 18, 2026)